PDCD1 and non-small cell lung carcinoma: PD-1+CD4+ T cells, representing broadly activated CD4+ T cells, also showed significant positive correlations with pCR in NSCLC patients (n = 27) [114] and with durable clinical benefit, PFS, and OS in GC patients (n = 169) [115], all of whom received aPD-1 therapy combined with chemotherapy.